Abstract

The present invention relates to a method for the production of therapeutic extracellular vesicles (EVs) from Mesenchymal Stem Cells by applying a direct pulsed electrical stimulation to said Mesenchymal Stem Cells. Furthermore, the present invention also discloses the EVs, the composition or the kit comprising them, and their use in regenerative therapy and the delivery of drugs.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• C12N 5/079 - Neural cells
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 5/09 - Tumour cells

Abstract

The invention relates to the use of a CRHR1 agonist, or composition comprising it, in the treatment and/or prevention of social anxiety disorders such as separation anxiety or avoidant personality disorders, particularly the use of the corticotropin-releasing hormone (CRH) as CRHR1 agonist.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

The invention pertains to means and methods for the detection of telomere fusion events, and the use of such means and methods in the detection and diagnosis of a disease associated with telomere fusion events, such as a cancer disease.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention provides a method for generating cells polarized to a M2 phenotype, comprising culturing mononuclear phagocyte system cells in a suitable culture medium comprising lactic acid or a lactate derivative, and subjecting the cells to a period of hypoxia followed by a period of re-oxygenation. The present invention also provides compositions comprising the cells obtained with the method defined herein and uses thereof.

IPC Classes  ?

• C12N 5/0786 - MonocytesMacrophages

Abstract

The present invention relates to an antibody, or an antigen binding fragment thereof, and to the CAR T-cell comprising the antigen binding fragment of said antibody. The invention also discloses to the polynucleotides encoding said antibody, the vector, the cells, the antibody-drug conjugate, and the composition comprising the antibody, the antigen binding fragment thereof, and/or to the CAR T-cell, all of them being useful in the treatment and/or prevention of leukemia, more preferably T-cell acute lymphoblastic leukemia (T-ALL), still more preferably T-ALL pre-TCR+, in a subject.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

A propagation-defective, replication-competent RNA replicon derived from the SARS-CoV-2 coronavirus that comprises a polynucleotide sequence SEQ_ID 2 or a variant of SEQ_ID 2 having at least 80% identity, more preferably 85% identity, even more preferably at least 90% identity, and even more preferably 91% or 92% or 93% or 94% or 95% or 96% or 97% or 98% or even up to 99% identity with respect to the SEQ_ID 2 polynucleotide sequence, wherein the variant of SEQ_ID2 does not comprise sequences suitable for expressing an ORF8 protein, wherein the ORF8 protein is encoded by a gene having at least 80% identity to the sequence of SEQ_ID36, methods of preparation thereof and the use in vaccine compositions.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention is directed to methods of amplifying a nucleic acid molecule using a thermostable primase/polymerase protein, TthPrimPol, of a thermophile bacterial strain of Thermus thermophilus SG0.5JP17-16, and the production of particular DNA molecules from DNA amplified by such methods. Amongst others, the present invention discloses primer-free methods, comprising TthPrimPol2, for amplification of low concentrations of DNA or RNA.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6844 - Nucleic acid amplification reactions
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12N 15/64 - General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

Abstract

The present invention relates to a screen-printed electrode (1) for detecting a pollutant in a water sample, comprising: a substrate (2); a plurality of conductive tracks (3); an electrochemical cell (4), further comprising a working electrode (5), a pseudo-reference electrode (6) and an auxiliary electrode (7); and an insulating layer (8). Advantageously, said electrode comprises a filtering element (9) impregnated with an electrolyte, which not only filters the water sample received by the electrochemical cell (4), but also preconditions the sample without any user intervention. Therefore, the screen-printed electrode of the invention saves time in pre-processing samples for water pollution analysis while avoiding any possible contamination thereof by user manipulation.

IPC Classes  ?

• G01N 33/18 - Water
• G01N 27/30 - Electrodes, e.g. test electrodesHalf-cells
• G01N 27/48 - Systems using polarography, i.e. measuring changes in current under a slowly-varying voltage

Abstract

The invention provides mitochondria-targeted chemiluminescent agents and their use in methods of photodynamic therapy (PDT). In particular, the invention provides compounds of general formula (I), and their pharmaceutically acceptable salts: The invention provides mitochondria-targeted chemiluminescent agents and their use in methods of photodynamic therapy (PDT). In particular, the invention provides compounds of general formula (I), and their pharmaceutically acceptable salts: AL+B]n]x   (I) The invention provides mitochondria-targeted chemiluminescent agents and their use in methods of photodynamic therapy (PDT). In particular, the invention provides compounds of general formula (I), and their pharmaceutically acceptable salts: AL+B]n]x   (I) in which A represents a chemiluminescent moiety; each L, which may be the same or different, is either a direct bond or a linker; each B, which may be the same or different, represents a mitotropic moiety; n is an integer from 1 to 3, preferably 1; and x is an integer from 1 to 3, preferably 1. Such compounds find particular use in the treatment of deeply-sited tumours, e.g. glioblastoma multiforme (GBM), when used in combination with a photosensitizer or photosensitizer precursor.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a liposomal-based composition and to the use thereof as an agent for the impermeabilization of oral mucosae, therefore, said composition also relates to the use thereof as a medicinal product, particularly for preventing viral infections, such as SARS-CoV-2, and to the use thereof for preventing contaminants, such as biocides, from penetrating through the mucosae.

IPC Classes  ?

• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses
• A61P 39/00 - General protective or antinoxious agents
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Abstract

The present invention relates to antibodies that inhibit B-lactamases, for example class A B-lactamase from Mycobacterium abscessus, as well as related compositions, and uses of same for and/or preventing infections caused by B-lactamase-producing bacteria.

IPC Classes  ?

• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• A61P 31/04 - Antibacterial agents
• C07K 14/35 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Mycobacteriaceae (F)

Abstract

The present disclosure provides a compound of formula I, as well as complexes and compositions comprising a compound of formula I, wherein said compositions and complexes are useful for delivery of certain agents, including, for example, nucleic acids.

IPC Classes  ?

• C07H 15/10 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical containing unsaturated carbon-to-carbon bonds
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• C07H 1/00 - Processes for the preparation of sugar derivatives

Abstract

The present disclosure provides compounds, compositions, and complexes useful for delivery of certain agents, including, for example, nucleic acids.

IPC Classes  ?

• C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• C07H 1/00 - Processes for the preparation of sugar derivatives

Abstract

A device for water and air decontamination and disinfection is proposed. The device comprises a three-dimensional structure (10) made of electrically insulating ceramic material and having a tuned topology comprising air voids (11) of a given size and arranged following a given distribution; one or more sorbents (12) embedded within the three-dimensional structure (10), mixed with the air voids (11), and adapted to chemically functionalize the three-dimensional structure (10); and electrodes (13) comprising one or more types of electrodes, the electrode arrangement (13) being configured to operate as a sensor to perform real-time measurements of the passive electrical properties of the contaminants absorbed by the three-dimensional porous structure (10) using electrical impedance spectroscopy (EIS), and to operate as a heater to apply a destructive thermal process to the contaminants absorbed by the three-dimensional porous structure (10) using the one or more types of electrodes or additional conductive elements.

IPC Classes  ?

• B01J 20/04 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
• B01J 20/06 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group
• C02F 1/28 - Treatment of water, waste water, or sewage by sorption
• C02F 1/42 - Treatment of water, waste water, or sewage by ion-exchange
• C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
• C02F 1/461 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
• B01J 20/32 - Impregnating or coating
• C02F 1/02 - Treatment of water, waste water, or sewage by heating
• C02F 101/30 - Organic compounds
• C02F 103/00 - Nature of the water, waste water, sewage or sludge to be treated

Abstract

The present invention provides polynucleotides comprising: (a) a polynucleotide sequence of SEQ ID NO: 42 (SARS-CoV-2Δ[3, E, 6 and 7] mutant) or SEQ ID NO: 43 (SARS-CoV-2Δ[3, E, 7 and 8] mutant); or (b) a variant of SEQ ID NO: 42 or a variant of SEQ ID NO: 43, wherein the variant has at least 96 % identity, preferably at least 97 % or at least 98 % or at least 99 % identity to SEQ ID NO: 42 or SEQ ID NO: 43. The invention further provides Virus Like Particles (VLPs) comprising these polynucleotides, methods of producing the same and vaccines comprising the VLPs or the polynucleotides.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors

Goods & Services

Plants; Seeds; Germ (Seed -) for botanical purposes; Seeds for fruit; Crop seeds; Seeds; Vegetable seeds; Seeds for flowers; Seeds, bulbs and seedlings for plant breeding, all for plant varieties. Agricultural research; Plant genetics research; Scientific and industrial research.

Goods & Services

Plants; Seeds; Germ (Seed -) for botanical purposes; Seeds for fruit; Crop seeds; Seeds; Vegetable seeds; Seeds for flowers; Seeds, bulbs and seedlings for plant breeding, all for plant varieties. Agricultural research; Plant genetics research; Scientific and industrial research.

Abstract

The present invention refers to the medical field. Particularly, the present invention refers to compounds of Formula I or Formula II for use in the treatment of frontotemporal dementia or frontotemporal lobar dementia.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Methods and materials for recombinantly producing apocarotenoids from transgenic plants, and more particularly, tomato and potato plants, expressing heterologous genes from Crocus sativus, the saffron plant, under the control of specific promoters. Moreover, the genetic constructs including the heterologous genes are also related, and the use thereof for the expression in plants and to a method for obtaining transgenic plants which express the genetic construct mentioned above, and which have a high concentration of apocarotenoids products, in particular crocins and picrocrocins. Furthermore, the the food products obtained from such transgenic plants are also related, nutraceutical and pharmaceutical compositions including thereof and the use of such compositions as medicine, preferably for the treatment of neurodegenerative diseases such as Alzheimer's disease.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

Disclosed is an apparatus and a method. Spin-splitting is induced at a superconductor and spin-polarization facilitated for tunneling across a tunnel barrier so that electric current across the tunnel barrier between a conductor and the superconductor flows primarily in one direction.

IPC Classes  ?

• H10N 50/10 - Magnetoresistive devices
• H10N 50/85 - Materials of the active region
• H10N 60/10 - Junction-based devices

Abstract

A first aspect of the present invention is related to a method for manufacturing an emitter for electrospray generators. The method comprising the steps of providing a substrate, presenting a plate and at least one protrusion, and then nanotexturizing the outer surface of the at least one protrusion. The present invention, according to a second aspect, also relates to the emitter resulting of the manufacturing method, the electrospray generator comprising the emitter according to the present invention and an electric space propulsion device comprising at least one electrospray generator thereof.

IPC Classes  ?

• B05B 5/053 - Arrangements for supplying power, e.g. charging power
• B05B 5/057 - Arrangements for discharging liquids or other fluent material without using a gun or nozzle
• B05B 5/16 - Arrangements for supplying liquids or other fluent material

Abstract

A neurocomputational electrochemical sensing device (1) is proposed for predicting properties of a substance. The device (1) comprises: a plurality of electrochemical sensors constituting a sensor array (3), the sensors being sensitive to sensed attributes advantageous to predict a set of properties of interest of the substance, each sensor being configured to output a sensor output signal indicative of a sensor response of the respective sensor to measurable changes in the sensed attributes of the substance; a readout circuit (5) for biasing the sensors and for conditioning the sensor output signals into readout circuit output signals to facilitate further processing of the sensor responses; and an artificial neural network processor (7) for processing the readout circuit output signals, the processor (7) comprising neurons interconnected by synapses, the processor (7) being configured to output a set of processor output signals whose signal values are indicative of the properties to predict. The sensor array (3) comprises first electrochemical sensors selective to properties correlated with the desired properties to predict, and second electrochemical sensors sensitive primarily to the main interferents of the substance. The neurons and/or the synapses are configured to be trained to compensate for sensor drift and/or cross-sensitivities upon generating the processor output signals.

IPC Classes  ?

• G01N 27/327 - Biochemical electrodes
• G06N 3/0499 - Feedforward networks

Abstract

Methods for processing a crude oil feedstock include introducing a crude oil stream to a reactive distillation unit to remove conradson carbon and metals from the crude oil stream and generate a distillate stream having a mean boiling point distribution less than the crude oil stream and passing the distillate stream in a gaseous form in a continuous manner and without further processing to a catalytic cracking reactor that cracks the distillate stream to form a petrochemical product stream including light olefins and BTX. The catalytic cracking reactor includes a cracking catalyst and a susceptor material dispersed throughout the catalytic cracking reactor. Further, the catalytic cracking reactor operates at a temperature of 300° C. to 800° C. with heating from magnetic induction of the susceptor material.

IPC Classes  ?

• C10G 55/06 - Treatment of hydrocarbon oils, in the absence of hydrogen, by at least one refining process and at least one cracking process plural serial stages only including at least one catalytic cracking step
• B01J 8/04 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes with stationary particles, e.g. in fixed beds the fluid passing successively through two or more beds

Abstract

Methods for processing a crude oil feedstock include introducing a crude oil stream to a reactive distillation unit to remove conradson carbon and metals from the crude oil stream and generate a distillate stream having a mean boiling point distribution less than the crude oil stream and passing the distillate stream in a gaseous form in a continuous manner and without further processing to a catalytic cracking reactor operating at a temperature of 300° C. to 800° C. with a cracking catalyst disposed therein that cracks the distillate stream to form a petrochemical product stream including light olefins and BTX.

IPC Classes  ?

• C10G 55/06 - Treatment of hydrocarbon oils, in the absence of hydrogen, by at least one refining process and at least one cracking process plural serial stages only including at least one catalytic cracking step
• B01D 3/00 - Distillation or related exchange processes in which liquids are contacted with gaseous media, e.g. stripping

Abstract

Methods for processing a crude oil feedstock include introducing a crude oil stream into a reactive distillation unit in order to remove the Conradson carbon residue and the metals from the crude oil stream and to generate a distillate stream having a mean boiling point distribution of less than that of the crude oil stream, and continuously guiding the distillate stream in a gaseous form without further processing to a catalytic cracking reactor that cracks the distillate stream to form a petrochemical product stream which includes light olefins and BTX. The catalytic cracking reactor includes a cracking catalyst and a susceptor material dispersed throughout the catalytic cracking reactor. Further, the catalytic cracking reactor operates at a temperature of 300°C to 800°C with heating by magnetic induction of the susceptor material.

IPC Classes  ?

• C10G 7/00 - Distillation of hydrocarbon oils
• C10G 55/06 - Treatment of hydrocarbon oils, in the absence of hydrogen, by at least one refining process and at least one cracking process plural serial stages only including at least one catalytic cracking step
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• B01J 37/00 - Processes, in general, for preparing catalystsProcesses, in general, for activation of catalysts
• C10G 32/02 - Refining of hydrocarbon oils by electric or magnetic means, by irradiation, or by using microorganisms by electric or magnetic means

Abstract

Methods for processing a crude oil feedstock include introducing a crude oil stream into a reactive distillation unit in order to remove the Conradson carbon residue and the metals from the crude oil stream and to generate a distillate stream having a mean boiling point distribution of less than that of the crude oil stream, and passing the distillate stream in a gaseous form in a continuous manner and without further processing to a catalytic cracking reactor operating at a temperature of 300°C to 800°C with a cracking catalyst disposed therein that cracks the distillate stream to form a petrochemical product stream including light olefins and BTX.

IPC Classes  ?

• C10G 7/00 - Distillation of hydrocarbon oils
• C10G 55/06 - Treatment of hydrocarbon oils, in the absence of hydrogen, by at least one refining process and at least one cracking process plural serial stages only including at least one catalytic cracking step
• C10G 11/20 - Catalytic cracking, in the absence of hydrogen, of hydrocarbon oils by direct contact with inert heated gases or vapours

Abstract

TthTthPrimPol) which continuously synthesizes suitable DNA primers on the RCA product to trigger a hyperbranched rolling circle amplification (HRCA), that can be directly analyzed by any detection method. Variants of phi29 DNApol and their use in this and other amplification methods are also provided herein.

IPC Classes  ?

• C12Q 1/6855 - Ligating adaptors
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

The invention relates to an infiltrated porous polymer blend membrane which comprises an infiltrated liquid, a first polymer which forms a gel with the infiltrated liquid, and a second polymer which is insoluble and non-swellable in the infiltrated liquid. The invention also relates to the process to obtain said membrane and to its use as a component of sensors, actuators, molecular transporters, biomedical devices, capacitors, and batteries.

IPC Classes  ?

• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 71/06 - Organic material
• H01M 50/414 - Synthetic resins, e.g. .thermoplastics or thermosetting resins

Abstract

The invention relates to a method for obtaining graphene materials selected from coke oxide, graphene oxide and graphene from green coke, comprising a basic treatment and subsequently an acid treatment of the starting material.

IPC Classes  ?

• C01B 32/182 - Graphene
• C01B 32/184 - Preparation
• C01B 32/19 - Preparation by exfoliation
• C01B 32/192 - Preparation by exfoliation starting from graphitic oxides
• C01B 32/196 - Purification
• C01B 32/198 - Graphene oxide
• C01B 32/23 - Oxidation

Abstract

The invention relates to compositions comprising one or more essential oils (EOs). Further disclosed are processes for generating said compositions and incorporating the same in a substrate, a material incorporating said compositions and uses thereof.

IPC Classes  ?

• A01N 65/22 - Lamiaceae or Labiatae [Mint family], e.g. thyme, rosemary, skullcap, selfheal, lavender, perilla, pennyroyal, peppermint or spearmint
• A01N 65/24 - Lauraceae [Laurel family], e.g. laurel, avocado, sassafras, cinnamon or camphor
• A01N 65/28 - Myrtaceae [Myrtle family], e.g. teatree or clove
• A01N 65/34 - Rosaceae [Rose family], e.g. strawberry, hawthorn, plum, cherry, peach, apricot or almond
• A01N 65/44 - Poaceae or Gramineae [Grass family], e.g. bamboo, lemon grass or citronella grass
• A01N 25/08 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
• A01N 25/10 - Macromolecular compounds
• A01N 25/28 - Microcapsules
• A01N 25/34 - Shaped forms, e.g. sheets, not provided for in any other group of this main group
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A01P 17/00 - Pest repellants

Abstract

The invention relates to a positively charged peptide capable of non-covalently interact with negatively charged extracellular vesicles or nanoparticles. Said peptide is a fragment of the bacterial protein P40 and shows better interaction capabilities that the entire bacterial protein P40. The peptide of the invention can also be linked to a targeting element, such as targeting peptide, DNA aptamer, RNA aptamer, a protein, an antibody or a fragment thereof that binds to a target molecule, therefore it can be used for the targeted delivery of extracellular vesicles or nanoparticles further comprising a bioactive agent to a target cell, tissue or particle like a virus, that comprise the target molecule. Therefore, the present invention also relates to a carrier complex comprising the peptide of the invention non covalently bound to an extracellular vesicle or nanoparticle comprising a bioactive agent and its uses.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C07K 19/00 - Hybrid peptides
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequenceDerivatives thereof
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to a chimeric protein and a biosensor system based on said chimeric protein that enable the binding of an extracellular target antigen and the generation of a signal upon recognition. The chimeric protein of the present invention comprises (i) an antigen binding domain, (ii) at least one β-barrel domain from an autotransporter, and (iii) a reporter protein domain comprising a partner of a split protein luminescence system, wherein domain (ii) is bound to domain (i) by one end and to domain (iii) by the other end. The present invention also discloses a host cell comprising at least two chimeric proteins of the invention complementary each other as an in vitro antigen detection system.

IPC Classes  ?

• C07K 14/245 - Escherichia (G)
• C07K 14/24 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
• C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching

Abstract

The present invention relates to 1,2-dihydroquinoline-2-ones of formula (I): The present invention relates to 1,2-dihydroquinoline-2-ones of formula (I): The present invention relates to 1,2-dihydroquinoline-2-ones of formula (I): or a pharmaceutically acceptable salt or solvate thereof, for its use in the treatment of limb girdle muscular dystrophy.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention relates to 2,4-disubstituted thiadiazolidinones of formula (I): The present invention relates to 2,4-disubstituted thiadiazolidinones of formula (I): The present invention relates to 2,4-disubstituted thiadiazolidinones of formula (I): or a pharmaceutically acceptable salt or solvate thereof, for its use in the treatment of limb girdle muscular dystrophy.

IPC Classes  ?

• A61K 31/433 - Thiadiazoles
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention relates to a method for trapping particles in an array of trapping sites, each trapping site being an optical tweezer creating an attractive energy potential for the particles, the optical tweezer being created by a first laser beam (20), each trapping site being capable of trapping a maximum number of particles, the method comprising: - loading particles in the trapping sites while detecting the presence of a particle in each trapping site, and - each time the presence of a maximum number of particles has been detected in a trapping site, applying a repulsive energy potential on said trapping site using a second laser (26) beam such that the total energy potential for the particles, has a global minimum, enabling to keep the particle trapped in the trapping site while surrounding the trapping site with a repulsive barrier.

IPC Classes  ?

• G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

It consists of a system for palpation of the rectal face of the prostate that transforms the information collected into objective, reproducible and useful information. The system makes it possible to identify areas of high rigidity reaching the entire peripheral area, transforming a diagnostic maneuver for prostate cancer into an objective one, which until now has been subjective and unreliable. All this in a short space of time, carried out in a less aggressive and more objective way than rectal examination. The device consists of a manual electronic instrument with a handle (1) and a scanning rod (3), which includes at least two concentric force/pressure sensors of different heights, as well as an ultrasonic imaging system which, through means of connection to external devices for analysis/control, allows the data obtained to be analyzed and the anatomy of the prostate being analyzed to be visualized in real time.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies

Abstract

The present invention relates to an aqueous-based conductive paint with different viscosities and to the procedure for its obtaining. Said paint comprises a carbon nanomaterial as an electrically conductive medium, a nanocrystalline cellulose as a dispersant and graphene oxide that can be dispersed in water as a thickener.

IPC Classes  ?

• C09D 5/24 - Electrically-conducting paints
• C01B 32/174 - DerivatisationSolubilisationDispersion in solvents
• C08K 3/04 - Carbon
• C08L 1/00 - Compositions of cellulose, modified cellulose, or cellulose derivatives
• C09D 7/61 - Additives non-macromolecular inorganic
• C09D 7/40 - Additives
• C09D 101/00 - Coating compositions based on cellulose, modified cellulose, or cellulose derivatives
• C01B 32/198 - Graphene oxide

Abstract

The present invention relates to a monoclonal antibody that specifically binds to an epitope comprising the amino acid sequence SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5 and capable of blocking the binding of IL-13 to IL13Rα2 or inhibiting the IL13/IL13Rα2 signaling, as well as the antiserum, the kit and the pharmaceutical composition comprising said monoclonal antibody. The invention also relates to the use of the antibody, the antiserum and the pharmaceutical composition in the treatment of cancer, specifically, cancer metastasis.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/04 - Antineoplastic agents specific for metastasis
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a hierarchical composite material comprising a discontinuous layer of titanium oxide particles dispersed on the surface of a core formed by a mineral particle. The invention also relates to a method for obtaining said material by applying mechanical forces to a dry mixture of titanium oxide particles and minerals. The product of the invention is useful as an opacifier and/or whitening agent in the formulation of paints and plastics.

IPC Classes  ?

• C09C 1/02 - Compounds of alkaline earth metals or magnesium
• C04B 35/628 - Coating the powders
• C09C 3/06 - Treatment with inorganic compounds
• C09D 5/02 - Emulsion paints

Abstract

The present disclosure provides for catalytic transformation to convert ethylene and/or α-olefins to higher olefins. Specifically, this disclosure provides for methods of catalyzing alkene oligomerization reactions and the making of catalytic precursors. In some aspects, the disclosure provides for catalyst precursors and catalytic ethylene oligomerization reaction methods and techniques that demonstrate the tendency of ethylene dimerization to yield creation of terminal 1-butene, while also highlighting how the characteristics of catalysis hinge on the specific identity of the ligands.

IPC Classes  ?

• C07C 2/32 - Catalytic processes with hydrides or organic compounds as complexes, e.g. acetyl-acetonates
• C07F 15/04 - Nickel compounds

Abstract

nn-β-D-fructofuranoside-(2→X)-R Formula I

IPC Classes  ?

• C07H 3/04 - Disaccharides
• C07H 3/06 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• C07H 1/08 - SeparationPurification from natural products
• A23L 33/26 - Polyol polyesters, e.g. sucrose polyestersSynthetic sugar polymers, e.g. polydextrose
• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins

Abstract

The present invention relates to the use of an enzyme which comprises an amino acid sequence with, at least, a 80% sequence identity to sequence SEQ ID NO: 1, for fumonisin degradation in a sample. Furthermore, the present invention relates to a method for fumonisin degradation, based on the incubation of the contaminated sample with an enzyme comprising an amino acid sequence with, at least, a 80% sequence identity to sequence SEQ ID NO: 1.

IPC Classes  ?

• C12P 7/42 - Hydroxy carboxylic acids
• C12P 7/44 - Polycarboxylic acids
• C12P 13/00 - Preparation of nitrogen-containing organic compounds
• C12N 9/18 - Carboxylic ester hydrolases
• A01N 63/50 - Isolated enzymesIsolated proteins

Goods & Services

Nutritive substances for microorganisms; Medicines for intestinal disorders; Pharmaceutical preparations for the treatment of disorders caused by bacteria; Pharmaceutical preparations for the prevention of diseases caused by bacteria; Immunotherapeutic agents for bacterial infections; Pharmaceutical preparations for the treatment of digestive diseases; Medicine; Pharmaceutical drugs; Biological preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical products for the treatment of infectious diseases; Pharmaceutical preparations for the prevention of inflammatory diseases; Pharmaceutical preparations for the prevention of autoimmune diseases; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the prevention of diseases of the metabolic system; Pharmaceutical preparations for the treatment of inflammatory diseases; Pharmaceutical preparations for the prevention of inflammatory disorders; Pharmaceutical preparations for the treatment of inflammatory disorders; Pharmaceutical preparations for treating metabolic disorders; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating gastrointestinal disorders; Pharmaceutical preparations for the treatment of diseases of the metabolic system; Pharmaceutical preparations for the treatment of autoimmune disorders. Scientific research for medical purposes; Research into new products; Research and development in the field of microorganisms and cells; Research and development in the field of biotechnology.

Abstract

The present invention relates to a nanomechanical mass flow meter and controller device for open nanofluidic systems. Said device is based on the integration of semiconductor nanowires, either as open nanofluidic channels or as mass flow meters. Thanks to this configuration, the flow of conducting liquids along the surface of a semiconductor nanowire can be characterized at room conditions by applying a small bias voltage between the nanowire and a conductive support that sustains an ionic liquid reservoir droplet. Around 2- 3 V, the conducting liquid can be made to flow steadily along the nanowire with both great degree of control and high flow rate measurement sensitivity. This technology opens unprecedented perspectives for the development of open nanofluidic applications, for which although several mechanisms to induce liquid flow have been explored, a technology that provides accurate real-time measurements of mass flow had never been proven.

IPC Classes  ?

• G01F 1/00 - Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow
• B01J 4/00 - Feed devicesFeed or outlet control devices
• B01J 4/02 - Feed devicesFeed or outlet control devices for feeding measured quantities of reagents
• G01F 15/00 - Details of, or accessories for, apparatus of groups insofar as such details or appliances are not adapted to particular types of such apparatus

Abstract

The present invention relates to African Swine Fever (ASF) attenuated viruses wherein the genes EP402R and O174L have been inactivated, which can be used as a vaccine. The attenuated viruses protects pigs against subsequent challenge with virulent virus. The present invention also relates to the use of such attenuated viruses to treat and/or prevent ASF.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

New core-shell microparticles based on bacterial cellulose (BC) and polyhydroxyalkanoates (PHAs) have been obtained by coaxial electrospraying. These particles are spherical, reproducible and stable. The core-shell of the particle is composed of a BC-PHA grafted polymer that ensures a good environment for encapsulating bioactive cargos. The polyhydroxyalkanoates (PHAs) shell provides the thin film that maintains the spherical shape of the particle.

IPC Classes  ?

• C08B 3/12 - Preparation of cellulose esters of organic acids of polybasic organic acids
• C08G 63/91 - Polymers modified by chemical after-treatment
• C08J 3/12 - Powdering or granulating
• C08L 1/10 - Esters of organic acids

Abstract

The invention relates to a device for measuring the dose delivered through a radiosensitive film under exposure to ionizing radiations, to a system comprising such device and to the use of such device. More particularly, the device comprises a reflection film; at least one light source; a radiosensitive film; and an optical sensor system comprising a 2-D array of one or more photoresistor units and/or semiconductor units. The present invention also relates to a system comprising the device previously described; a readout integrated circuit unit connected to the optical sensor system of the device; and a processing unit connected to the readout integrated circuit. The present invention also relates to the use of a device as previously described.

IPC Classes  ?

• G01T 1/04 - Chemical dosimeters
• G01T 1/105 - Read-out devices

Abstract

Apparatus and methods for sampling air-borne particles. According to one embodiment a nozzle is used to generate a jet of fog that includes a gas and liquid droplets. The jet of fog is formed by the nozzle in a way to cause particles in the air surrounding the jet of fog to be drawn into the jet of fog and to further cause the particles to aggregate with the liquid droplets inside the jet of fog. A sample collecting surface is located opposite and spaced apart from an outlet of the nozzle. The sample collecting surface is preferably sloped so that the liquid sample can be forced by gravity off the collecting surface and into a liquid sample container. Inside the jet of fog and on the sample collection surface the liquid droplets merge with one another to form larger sized droplets that are collectable in the liquid sample container.

IPC Classes  ?

• G01N 1/22 - Devices for withdrawing samples in the gaseous state

Abstract

The invention relates to methods for determining the prognosis of a patient suffering colorectal cancer, for selecting an adjuvant chemotherapy for said patient and for selecting a patient suffering colorectal cancer to receive adjuvant combination chemotherapy. The invention also relates to a computer implemented method for determining the prognosis of a patient suffering colorectal cancer, or for selecting an adjuvant chemotherapy for a patient suffering colorectal cancer, or for selecting a patient suffering colorectal cancer to receive adjuvant combination chemotherapy and to a computer program to implement this method.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

A chemiresistive sensor has a low limit for detecting NO2 at ambient temperature. An active layer of the sensor includes a few-layer graphene material. The response of the sensor is not altered by relative humidity, and the sensor also demonstrates very low interference with ammonia, allowing this interference to be disregarded in the measurements.

IPC Classes  ?

• G01N 27/12 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon absorption of a fluidInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon reaction with a fluid
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

A system and method are provided of controlling a plurality of optical traps. The method comprises: generating the plurality of optical traps, each optical trap ("i") having a trap intensity; measuring trap loading rates for each trap; minimizing differences between trap loading rates of different traps, the minimizing comprising adjusting of at least some of the traps the trap intensity to a further trap intensity based on the trap loading rates.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

The device limits the leakage current in an electronic system for recording electrophysiological signals, where the transducer element is an active device, the device comprising an active transducer (1), intended to contact a human tissue, connected to a transimpedance amplifier (2), and a first resistor (6) connected parallel to the transimpedance amplifier (2), an alternate voltage source (7) and a direct voltage source (8), both connected to the active transducer (1), a first capacitor (3) connected between the alternate voltage source (7) and the active transducer (1), a second resistor (4) connected between the direct voltage source (8) and the active transducer (1), parallel with the first capacitor (3) and the alternate voltage source (7), and a second capacitor (5), connected between the active transducer (1) and the transimpedance amplifier (2).

IPC Classes  ?

• A61B 5/31 - Input circuits therefor specially adapted for particular uses for electroencephalography [EEG]
• A61B 5/304 - Switching circuits
• H03H 11/02 - Multiple-port networks

Abstract

Pupae counting device that allows the automatic quantification of the youth-adult transition in groups of flies, like Drosophila. It comprises a circular platform, one or more tube holders positioned on the platform, one or more sample tubes, inserted into each tube holder, and intended to contain the pupae, a camera for recording video and images, directed towards the platform, a central motor linked and rotating the platform in front of the camera, until a sample tube of interest is positioned in front of the camera, and an external motor positioned beside the platform, for rotating the sample tube of interest 360° over itself in front of the camera.

IPC Classes  ?

• A01K 29/00 - Other apparatus for animal husbandry
• G06M 7/00 - Counting of objects carried by a conveyor
• G06M 11/00 - Counting of objects distributed at random, e.g. on a surface
• H04N 5/76 - Television signal recording
• G06T 7/00 - Image analysis
• H04N 23/56 - Cameras or camera modules comprising electronic image sensorsControl thereof provided with illuminating means

Abstract

The present disclosure relates to a see-through binocular device (100) for far, intermediate and near distances, which comprises two see-through optical modules 5 (110a, 110b), each see-through optical module (110a, 110b) configured for projecting without inversion an image (1a, 1b, 1c; 2a, 2b, 2c) of an object (1, 2) on a first plane each see-through optical module (110a, 110b) comprising: i. an optical element with variable optical power (120); and ii. an optical projection system (130) configured for projecting the optical 0 element with variable optical power (120) on a second plane (120'); wherein: - the input optical axes (113a, 113b) of the two see-through optical modules (110a, 110b) intersect at a plane corresponding to a near distance, such that their fields of view (112a, 112b) overlap completely or almost completely for viewing objects 5 located at a near distance. The disclosure also relates to a system and method for determining sensory eye dominance and/or for determining sensory eye dominance strength. 0

IPC Classes  ?

• A61B 3/08 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing binocular or stereoscopic vision, e.g. strabismus

Abstract

The invention relates to a spectral shaper illumination device and a method for providing a tunable spectrally shaped focused spectrally split beam modulated in intensity and/or in a wavelength range with respect to the light source. Furthermore, the invention refers to a method for optical spectroscopic characterization of optical and/or optoelectronic materials and/or devices using said spectral shaper illumination device. Moreover, the present invention refers to an optical metrology system comprising the spectral shaper illumination device. The invention is therefore of interest for the optical and/or optoelectronic industries and for the optical metrology industries.

IPC Classes  ?

• F21S 8/00 - Lighting devices intended for fixed installation
• G01J 3/10 - Arrangements of light sources specially adapted for spectrometry or colorimetry
• G01J 3/02 - SpectrometrySpectrophotometryMonochromatorsMeasuring colours Details

Abstract

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. It also relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in medicine, in particular for the prevention of treatment of infection by coronavirus. The invention also relates to a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof formula (I).

IPC Classes  ?

• C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 31/12 - Antivirals

Abstract

The present disclosure relates to an ocular bandage (100, 100a), the ocular bandage (100, 100a) comprising: - a membrane (10) comprising, at least, silk fibroin, obtained by means of a porogen and a crosslinker agent; and - a central portion (20), the central portion blocking light within a pre-established wavelength range; and wherein - the central portion (20) is dimensioned with respect to the membrane (10) such that there are at least outwardly located portions (30) of the membrane that are not covered by the central portion. The disclosure also relates to a kit for implanting an ocular bandage (100, 100a) onto ocular tissue, and to a method for implanting the ocular bandage by photobonding.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses
• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present disclosure relates to an ocular bandage (100, 100a), the ocular bandage (100, 100a) comprising: - a membrane (10) comprising, at least, silk fibroin, obtained by means of a porogen and a crosslinker agent; and - a central portion (20), the central portion blocking light within a pre-established wavelength range; and wherein - the central portion (20) is dimensioned with respect to the membrane (10) such that there are at least outwardly located portions (30) of the membrane that are not covered by the central portion. The disclosure also relates to a kit for implanting an ocular bandage (100, 100a) onto ocular tissue, and to a method for implanting the ocular bandage by photobonding.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

An ultrasonic transducer (10) for generating an ultrasonic wave (100) comprising: - a sound emitting surface (12) having a shape of a spherical segment with a sphere radius (13); - the sound emitting surface (12) having a through hole (11) coinciding with the first segment base having smaller first radius (r1) than the second radius (r2) of the second segment base; - the ultrasonic wave generated by the sound emitting surface (12) is a focused ultrasonic beam which, at a focal point (14), produces a beam spot (101) having: - an axial dimension (111) along an axis of symmetry of the spherical segment between 0.50 mm and 1.1 mm; and - a lateral dimension (112) perpendicular to the axis of symmetry of the spherical segment between 0.4 mm and 1.2 mm; - the ultrasonic wave has a frequency in the range from 300 kHz to 700 kHz; and in that - a distance between the second segment base and the focal point is between 24 mm to 64 mm. A system and a method for measuring biomechanical properties of ocular tissue are also disclosed.

IPC Classes  ?

• A61B 8/10 - Eye inspection
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• A61B 8/08 - Clinical applications

Abstract

Disclosed are apparatus and methods for sampling air-borne particles. According to one embodiment a nozzle is used to generate a jet of fog that includes a gas and liquid droplets of different sizes. The jet of fog is formed by the nozzle in a way to cause particles in the air surrounding the jet of fog to be drawn into the jet of fog and to further cause the particles to aggregate with the liquid droplets inside the jet of fog. A sample collecting surface is located opposite and spaced apart from an outlet of the nozzle. The sample collecting surface is preferably sloped so that the liquid sample can be forced by gravity off the collecting surface and into a vial or other liquid sample container. Inside the jet of fog and on the sample collection surface the liquid droplets merge with one another to form larger sized droplets that are collectable in the liquid sample container.

IPC Classes  ?

• G01N 1/22 - Devices for withdrawing samples in the gaseous state

Abstract

The present invention is in the field of biotechnology, in particular in the field of detection of pathogenic viruses, more particularly in the detection of single-stranded RNA (ssRNA) viruses. The present invention relates to an in vitro method for the detection of single- stranded nucleic acids, in particular ssRNA viruses, using the restriction enzyme FokI. The invention also relates to a kit comprising the means necessary for the detection of these nucleic acids and its use for this purpose.

IPC Classes  ?

• C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
• C12Q 1/6844 - Nucleic acid amplification reactions

Abstract

The present invention relates to the use of the soluble receptor sIFNAR2 in the treatment of SARS-CoV-2 coronavirus infection, and compositions comprising said protein.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• A61P 31/14 - Antivirals for RNA viruses

Abstract

An apparatus and a method for displacing and/or for changing a direction of an input light beam axis (BAA) of an input light beam is disclosed. The apparatus comprises: - a collimator (COL); - a first lens (ETL1) and a second lens (ETL2) having adjustable focal lengths, such that the optical axis of the collimator intersects the first lens at an offset (h1A) from its front principal point (PP1), and the second lens is arranged at a distance (d) from the first lens; - means for adjusting the focal length (f1A, f1B) of the first lens such that the focal length of the first lens sets an intersection point (IPA, IPB) between a light beam axis (LA, LB) outputted by the first lens and a target direction (TDA), parallel to the desired direction of a displaced and/or deflected light beam axis (DAA, DAB) of a light beam (DBA, DBB) outputted from the second lens; - means for adjusting the focal length (f2A, f2B) of the second lens such that the focal length of the second lens equal to the distance between the lenses d minus the distance of the first lens to the intersection point (IPA, IPB).

IPC Classes  ?

• G02B 26/10 - Scanning systems
• G02B 26/08 - Optical devices or arrangements for the control of light using movable or deformable optical elements for controlling the direction of light

Abstract

This invention is related to the general subject of the control of pathogens in plants, and in particular to the use of compositions which, when applied to plants, make them more resistant to the attack of said pathogens, particularly to Fusarium odoratissimum tropical race 4 (TR4).

IPC Classes  ?

• A01N 35/06 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical containing keto or thioketo groups as part of a ring, e.g. cyclohexanone, quinoneDerivatives thereof, e.g. ketals
• A01N 41/04 - Sulfonic acidsDerivatives thereof
• A01P 21/00 - Plant growth regulators

Abstract

The invention relates to a nanobody directed against the receptor binding domain (RBD) of spike protein from severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), to a fusion protein comprising said nanobody, and to a heavy chain antibody comprising two heavy chains, wherein each heavy chain comprises said fusion protein. The invention also relates to a bivalent construction comprising two nanobodies, wherein said two nanobodies are linked by a peptide bond. The invention also relates to a nucleic acid encoding the said nanobody, fusion protein or bivalent construction, to a vector comprising said nucleic acid, to a host cell comprising said nucleic acid or said vector, and to a pharmaceutical composition comprising said nanobody, fusion protein, heavy chain antibody or bivalent construction. The invention also relates to the medical uses of said nanobody, fusion protein, heavy chain antibody, bivalent construction or pharmaceutical composition for use in the treatment and/or prevention of an infection caused by SARS-CoV-2, and to a method for diagnosing an infection SARS-CoV-2 in a subject comprising contacting a sample from the subject with said nanobody, fusion protein, heavy chain antibody or bivalent construction.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The invention relates to a nanobody directed against the receptor binding domain (RBD) of spike protein from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to a fusion protein comprising said nanobody, and to a heavy chain antibody comprising two heavy chains, wherein each heavy chain comprises said fusion protein. The invention also relates to a bivalent construction comprising two nanobodies, wherein said two nanobodies are linked by a peptide bond. The invention also relates to a nucleic acid encoding the said nanobody, fusion protein or bivalent construction, to a vector comprising said nucleic acid, to a host cell comprising said nucleic acid or said vector, and to a pharmaceutical composition comprising said nanobody, fusion protein, heavy chain antibody or bivalent construction. The invention also relates to the medical uses of said nanobody, fusion protein, heavy chain antibody, bivalent construction or pharmaceutical composition for use in the treatment and/or prevention of an infection caused by SARS-CoV-2, and to a method for diagnosing an infection SARS-CoV-2 in a subject comprising contacting a sample from the subject with said nanobody, fusion protein, heavy chain antibody or bivalent construction.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The invention relates to a nanobody directed against the receptor binding domain (RBD) of spike protein from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to a fusion protein comprising said nanobody, and to a heavy chain antibody comprising two heavy chains, wherein each heavy chain comprises said fusion protein. The invention also relates to a bivalent construction comprising two nanobodies, wherein said two nanobodies are linked by a peptide bond. The invention also relates to a nucleic acid encoding the said nanobody, fusion protein or bivalent construction, to a vector comprising said nucleic acid, to a host cell comprising said nucleic acid or said vector, and to a pharmaceutical composition comprising said nanobody, fusion protein, heavy chain antibody or bivalent construction. The invention also relates to the medical uses of said nanobody, fusion protein, heavy chain antibody, bivalent construction or pharmaceutical composition for use in the treatment and/or prevention of an infection caused by SARS-CoV-2, and to a method for diagnosing an infection SARS-CoV-2 in a subject comprising contacting a sample from the subject with said nanobody, fusion protein, heavy chain antibody or bivalent construction.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to an isolated nucleotide acid sequence comprising a) the cDNAs of two strands of a target double-stranded RNA (dsRNA) separated by an autocatalytic intron flanked by exon fragments, and b) a plant viroid, wherein element (a) is inserted in the plant viroid sequence. The expression of this nucleotide sequence in a host cell, such as E. coli, along with a tRNA ligase, allows the production of high amounts of dsRNA specific for a target gene. This dsRNA can be used in the interfering RNA technology for silencing gene expression. Additionally, the present invention also relates to a method for producing said dsRNA.

IPC Classes  ?

• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli

Abstract

The present invention relates to compounds of formula (I), in addition to the use thereof for the treatment and/or prevention of diseases caused by protozoa, especially those belonging to the genus Leishmania or Trypanosoma. The present invention likewise relates to pharmaceutical compositions comprising said compounds. (I)

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• C07D 235/14 - Radicals substituted by nitrogen atoms
• C07D 213/06 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom

Abstract

An apparatus (10) for sampling air-borne particles, comprising a nozzle (1), which is used to generate a jet of fog (20) that includes a gas and liquid droplets of different sizes. The jet of fog (20) is formed by the nozzle in a way to cause particles in the air surrounding the jet of fog to be drawn into the jet of fog and to further cause the particles to aggregate with the liquid droplets inside the jet of fog. A sample collecting surface (30) is located opposite and spaced apart from an outlet of the nozzle. The sample collecting surface is preferably sloped so that the liquid sample can be forced by gravity off the collecting surface and into a vial or other liquid sample container. Inside the jet of fog and on the sample collection surface the liquid droplets merge with one another to form larger sized droplets that are collectable in the liquid sample container (32).

IPC Classes  ?

• G01N 1/22 - Devices for withdrawing samples in the gaseous state
• G01N 1/40 - Concentrating samples
• A61L 9/14 - Disinfection, sterilisation or deodorisation of air using sprayed or atomised substances
• B01D 5/00 - Condensation of vapoursRecovering volatile solvents by condensation
• B01J 8/12 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes with moving particles moved by gravity in a downward flow
• B01J 8/14 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes with moving particles moving in free vortex flow apparatus
• F24F 8/183 - Treatment, e.g. purification, of air supplied to human living or working spaces otherwise than by heating, cooling, humidifying or drying by separation, e.g. by filtering by centrifugal separation, e.g. using vortices

Abstract

A method estimates a full shape of a crystalline lens from measurements of the lens taken in-vivo by optical imaging techniques and include visible portions of the lens. The method includes receiving the in-vivo measurements of the lens, determining non-visible portions of the lens parting from the in-vivo measurements. Determining non-visible portions of the lens includes establishing a location of points which define an initial full shape of a crystalline lens, displacing these points by lengths following a directions to a location of a second set of points, which are estimated points of the full shape of the lens. The initial full shape of a crystalline lens is obtained from ex-vivo measurements and the lengths is estimated from the in-vivo measurements. A further method selects an intraocular lens implantable in an eye. Yet further, a data-processing system configured to determines a full shape of a crystalline lens.

IPC Classes  ?

• G06T 7/50 - Depth or shape recovery
• G06T 7/70 - Determining position or orientation of objects or cameras
• G06T 7/00 - Image analysis
• G06T 7/60 - Analysis of geometric attributes
• A61B 3/117 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for examining the anterior chamber or the anterior chamber angle, e.g. gonioscopes
• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions

Abstract

υinin vinin υinin vinin in ) to a laser beam entering the input facet (11) of the plasmonic multimode optical fiber (10).

IPC Classes  ?

• G02F 1/225 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour by interference in an optical waveguide structure
• G02B 6/00 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings
• G02B 6/26 - Optical coupling means

Abstract

The invention relates to an in vitro method for the diagnosis and/or prognosis of thyroid carcinoma, discriminating between benign and malignant nodules, by comparing the methylation level of the cytosine residue of various CpG sites, particularly the CpG sites at position 97,858,492-97,858,493 of the human chromosome 13, position 74,957,673-74,957,674 of the human chromosome 14 and/or position 5,672,830- 5,672,831 of the human chromosome 20. Further, the present invention relates to the use of the methylation levels of said CpG sites and the kit for in vitro determination of the methylation levels.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The invention relates to sulfated chitosan derivatives of formula (I), wherein the meanings for the various substituents are as disclosed in the description, for their use in the treatment and/or prevention of a viral infection, particularly wherein the viral infection is caused by SARS-CoV-2 such as COVID-19 or RSV.

IPC Classes  ?

• C08B 37/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• A61K 31/722 - ChitinChitosan

Abstract

The present invention refers to a gas sensor comprising a hybrid material of perovskite and graphene, to the method for obtaining said sensor and to the gas detection method using said sensor.

IPC Classes  ?

• G01N 27/04 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance
• C01B 32/182 - Graphene

Abstract

The invention relates to a waveguide and a polarisation splitter based on said waveguide, in which a rotation of an angle greater than zero is applied to a plurality of sections of a core material and a plurality of sections of a covering material, thereby achieving an independent control of the refractive indices of a zero-order transverse electric mode and a zero-order transverse magnetic mode. This document also describes a manufacturing method of said waveguide which allows the birefringence of the light that passes through the waveguide.

IPC Classes  ?

• F21V 8/00 - Use of light guides, e.g. fibre optic devices, in lighting devices or systems
• G02B 5/18 - Diffracting gratings
• G02B 6/028 - Optical fibres with cladding with core or cladding having graded refractive index

Abstract

The invention provides an anti-CCR9 antibody molecule for use in a method of treatment of cancer in a mammalian subject wherein the anti-CCR9 antibody molecule is administered simultaneously, sequentially or separately with a chemotherapeutic agent selected from the group consisting of: vincristine, docetaxel, paclitaxel, nanoparticle albumin-bound paclitaxel, and vinblastine, wherein said anti-CCR9 antibody molecule and said chemotherapeutic agent are not conjugated together. Also provided are related methods of treatment.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine

Abstract

The present invention relates to a method for decomposing CO2 into O2 and solid C in an electrochemical reactor, which comprises at least the following steps: i) introducing CO2 into a cathode chamber (1) containing at least one cathode fluid (2) with electrical conductivity > 5 mS/cm; ii) decomposing the CO2 in the cathode chamber by applying an electric field to the solid electrolyte (3), forming at least oxide ions (O2-), which are selectively transported through the solid electrolyte from the cathode chamber to an anode chamber (4), and solid carbon; iii) extracting, from the anode chamber, the O2 produced on the anode (5) from the ions transported in step ii); and iv) extracting, from the cathode chamber, the solid C formed in step ii).

IPC Classes  ?

• C25B 1/135 - Carbon
• C25B 11/033 - Liquid electrodes

Abstract

The present invention concerns an E. coli strains expressing high level of α-Gal, in particular selected in the group consisting of E. coli Nissle 1917 strain, E. coli O111 strain, E. coli O86:B7 strain, and mixture thereof, as a probiotic and/or feed additive and/or oral vaccine in a non-human animal, in particular fish and poultry, to prevent and/or reduce an infectious disease caused by a pathogen expressing α-Gal on its surface.

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23K 50/75 - Feeding-stuffs specially adapted for particular animals for birds for poultry
• A23K 50/80 - Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
• A61K 39/108 - EscherichiaKlebsiella
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The invention pertains to means and methods for the detection of telomere fusion events, and the use of such means and methods in the detection and diagnosis of a disease associated with telomere fusion events, such as a cancer disease.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The invention pertains to means and methods for the detection of telomere fusion events, and the use of such means and methods in the detection and diagnosis of a disease associated with telomere fusion events, such as a cancer disease.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

A propagation-defective, replication-competent RNA replicon derived from the SARS-CoV-2 coronavirus that comprises a polynucleotide sequence SEQ_ID 2 or a variant of SEQ_ID 2 having at least 80 % identity, more preferably 85% identity, even more preferably at least 90 % identity, and even more preferably 91 % or 92 % or 93 % or 94 % or 95 % or 96 % or 97 % or 98 % or even up to 99 % identity with respect to the SEQ_ID 2 polynucleotide sequence, wherein the variant of SEQ_ID2 does not comprise sequences suitable for expressing an ORF8 protein, wherein the ORF8 protein is encoded by a gene having at least 80% identity to the sequence of SEQ_ID36, methods of preparation thereof and the use in vaccine compositions.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a screen-printed electrode (1) for detecting a pollutant in a water sample, comprising: a substrate (2); a plurality of conductive tracks (3); an electrochemical cell (4), further comprising a working electrode (5), a pseudo-reference electrode (6) and an auxiliary electrode (7); and an insulating layer (8). Advantageously, said electrode comprises a filtering element (9) impregnated with an electrolyte, which not only filters the water sample received by the electrochemical cell (4), but also preconditions the sample without any user intervention. Therefore, the screen-printed electrode of the invention saves time in pre-processing samples for water pollution analysis while avoiding any possible contamination thereof by user manipulation.

IPC Classes  ?

• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

The invention relates to a new adhesive material with a reversible adhesion/separation capability, which can be remotely triggered via an energy source and that will facilitate the recycling of multi-layered packaging and its procedure of obtainment from solvent- borne polyol and isocyanate components in a single step process, from solvent-free polyol and isocyanate components in a two-step process or from isocyanate components in a single step process.

IPC Classes  ?

• C09J 175/14 - Polyurethanes having carbon-to-carbon unsaturated bonds
• C08G 18/75 - Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic
• C08G 18/42 - Polycondensates having carboxylic or carbonic ester groups in the main chain
• C08G 18/67 - Unsaturated compounds having active hydrogen
• B32B 7/12 - Interconnection of layers using interposed adhesives or interposed materials with bonding properties

Abstract

The present invention refers to a specific composition, which functions as an enzyme mimic or artificial enzyme, for assessing the presence of microorganisms in a test sample. On the other hand, the composition can be used as a medicament, preferably in the treatment of infections caused by said microorganisms. The composition comprises: a) a coordination polymer which in turn comprises a polymeric crystalline structure with a repeating core characterized by Formula I: M2L2(H2O)4 wherein: i. M is copper (II) ion, ii. L is an aromatic pseudo-peptide characterized by Formula II: H2I- bis-amino acid or Formula III: H2T-bis-amino acid, wherein T is terephthaloyl, I is isophthaloyl, and the amino acid is a L or D amino acid; and b) H2O2.

IPC Classes  ?

• B01J 31/16 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
• B01J 31/22 - Organic complexes
• A61K 38/00 - Medicinal preparations containing peptides
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/30 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase involving catalase

Abstract

The present invention relates to a screen-printed electrode (1) for detecting a pollutant in a water sample, comprising: a substrate (2); a plurality of conductive tracks (3); an electrochemical cell (4), further comprising a working electrode (5), a pseudo-reference electrode (6) and an auxiliary electrode (7); and an insulating layer (8). Advantageously, said electrode comprises a filtering element (9) impregnated with an electrolyte, which not only filters the water sample received by the electrochemical cell (4), but also preconditions the sample without any user intervention. Therefore, the screen-printed electrode of the invention saves time in pre-processing samples for water pollution analysis while avoiding any possible contamination thereof by user manipulation.

IPC Classes  ?

• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

The present invention relates to the treatment of T-cell acute lymphoblastic leukemia (T-ALLs) by means of immunotherapy with a monoclonal antibody which recognizes the pre-TCR receptor which, due to its presence in all phases of T-ALL pre-TCR+ development, can also be used as a leukemia-initiating cell (LIC) biomarker and as a therapeutic target useful for monitoring minimal residual disease and identifying compounds inhibiting the disease.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a multifunctional system stable in a physiological medium, which includes in the same platform an anti-carcinogenic molecule, an imaging agent and a directing molecule that interacts specifically with cancer-cell membrane receptors, the system allowing pathological tissue imaging and pharmacological action to be carried out jointly with high specificity. The intratumoral administration of the system facilitates selective diffusion to cancer cells and minimises the disadvantages of chemotherapy.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
• A61K 49/00 - Preparations for testing in vivo
• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• A61K 49/16 - AntibodiesImmunoglobulinsFragments thereof
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof

Abstract

122, n and m is defined in the description, to a pharmaceutical composition thereof and to their use as heparin antidotes in the control of blood coagulation.

IPC Classes  ?

• C07C 215/50 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
• C07C 215/64 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
• A61P 39/02 - Antidotes
• C07C 217/70 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring

Abstract

CoronaviridaeCoronaviridaein vitroin vitro and can efficiently impair virus replication and transcription. Furthermore, the lOHNPs are suitable for oral, intranasal or parenteral administration in combination with a pharmaceutical carrier.

IPC Classes  ?

• A61K 33/26 - IronCompounds thereof
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to novel, tailor-made alkaliphilic and thermotolerant laccases developed by enzyme directed evolution for use in wood conversion, biomass biorefineries and green chemistry.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12P 19/14 - Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase, e.g. by alpha-amylase

Abstract

Coronaviridae Severe acute respiratorysyndrome coronavirusCoronaviridae in vitro in vitro and can efficiently impair virus replication, transcription and production of infectious virus. Furthermore, the IONPs are suitable for oral, intranasal or parenteral administration in combination with a pharmaceutical carrier.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 33/26 - IronCompounds thereof
• A61P 31/14 - Antivirals for RNA viruses
• A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates

Abstract

The present disclosure provides compositions comprising an oligosaccharide of formula (I), wherein said compositions are useful for delivery of certain agents, including, for example, nucleic acids.

IPC Classes  ?

• C07H 15/14 - Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
• C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C07H 99/00 - Subject matter not provided for in other groups of this subclass
• C07H 1/00 - Processes for the preparation of sugar derivatives
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates a recombinant African swine fever virus (ASFV), characterized in that the genome of the recombinant ASFV comprises at least one miRNA target sequence, the miRNA target sequence is found within a gene that is essential for viral replication and the miRNA target sequence is specific for a miRNA which is expressed in a viral target cell.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention is related to an anatomical model for measuring the interaction of an exoskeleton with a biological limb assisted by said exoskeleton. The present invention is characterized by a special structure of the device formed by an inner structure comprising a first structural element and a second structural element. The first structural element and a second structural element are joined by means of a first joint, preferably with rotation capability. Likewise, the device comprises a first casing and a second casing, each of the casings covering the first structural element and a second structural element respectively. The device is further characterized in that each of the shells is divided into a plurality of segments and, each segment is attached to the internal structure by means of a sensor that allows to provide a signal representing the loads that the exoskeleton exerts on the region corresponding to that segment.

IPC Classes  ?

• G09B 23/30 - Anatomical models
• G09B 23/32 - Anatomical models with moving parts
• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• B25J 9/00 - Programme-controlled manipulators
• G09B 23/34 - Anatomical models with removable parts
• B25J 19/00 - Accessories fitted to manipulators, e.g. for monitoring, for viewingSafety devices combined with or specially adapted for use in connection with manipulators

Abstract

The present invention refers to splice shifting oligonucleotides (SSOs), targeting the downstream 3' splice acceptor site relative to microexons, which are mis-spliced in various diseases, particularly in neurological diseases like autism spectrum disorders (ASD) and schizophrenia.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

A modular artificial neural sensing system includes a hierarchical network of neural sensing units including a neuromimetic sensor array of artificial sensory synapses and sensory neurons for receiving physicochemical sensed signals and for outputting sensor output signals. An artificial neural network processor is adapted for processing the sensor output signals and includes processor neurons interconnected by processor synapses forming first connections and second connections. The processor outputs processor output signals. A first sensor interface feeds processed or unprocessed sensed signals into the processor. A second sensor interface receives output predicted signals from other neural sensing units and feeds processed or unprocessed output predicted signals into the processor. A signal decoder decodes the processor output signals and outputs decoder output signals. An error feedback module receives the decoder output signals and teaching signals for generating error signals depending on a difference between teaching signals and decoder output signals.

IPC Classes  ?

• G06N 3/04 - Architecture, e.g. interconnection topology

Abstract

The invention provides methods and materials for recombinantly producing apocarotenoids from transgenic plants, and more particularly, tomato and potato plants, expressing heterologous genes from Crocus sativus, the saffron plant, under the control of specific promoters. Moreover, the present disclosure also relates to the genetic constructs comprising the heterologous genes, and the use thereof for the expression in plants and to a method for obtaining transgenic plants which express the genetic construct mentioned above, and which have a high concentration of apocarotenoids products, in particular crocins and picrocrocins. Furthermore, the present disclosure also refers to the food products obtained from such transgenic plants, nutraceutical and pharmaceutical compositions comprising thereof and the use of such compositions as medicine, preferably for the treatment of neurodegenerative diseases such as Alzheimer's disease.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 9/10 - Transferases (2.)
• C12P 7/44 - Polycarboxylic acids

Abstract

The present invention relates to a series of N-sulfonlyurea derivative compounds, compounds of general formula (I), with pharmacological inhibitory activity of the NLRP3 inflammasome. The use of the compounds of general formula (I) as agents for treating preferably human diseases that involve an inflammatory process, preferably involving what are known as inflammasomes, preferably of the NLRP3 type, is claimed. These diseases include neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, inflammatory diseases, metabolic diseases, autoimmune diseases and generally any pathology caused by impaired biological functions in which the NLRP3 inflammasome is involved. The present invention has been developed in the field of pharmaceutical industry.

IPC Classes  ?

• C07D 307/56 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 17/06 - Antipsoriatics
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Abstract

A system for obtaining biomechanical parameters of ocular tissue includes an air-puff module to deliver an air-puff stimulus onto the ocular tissue, and an imaging device operatively coupled to the air-puff module. A system for obtaining biomechanical parameters of ocular tissue includes an air-puff module to deliver an air-puff stimulus onto the ocular tissue, and an imaging device operatively coupled to the air-puff module. The air-puff module includes a transparent window at its front with a transparent through hole for delivering the air-puff stimulus. The hole is aligned with an imaging device optical axis, such that the air-puff stimulus delivered onto the ocular tissue can be centred on an apex of the ocular tissue and made collinear with the optical axis. The transparent window and through hole allow continuity of imaging of the ocular surface. A system for obtaining biomechanical parameters of ocular tissue includes an air-puff module to deliver an air-puff stimulus onto the ocular tissue, and an imaging device operatively coupled to the air-puff module. The air-puff module includes a transparent window at its front with a transparent through hole for delivering the air-puff stimulus. The hole is aligned with an imaging device optical axis, such that the air-puff stimulus delivered onto the ocular tissue can be centred on an apex of the ocular tissue and made collinear with the optical axis. The transparent window and through hole allow continuity of imaging of the ocular surface. The imaging device captures the 3D coordinates of points distributed on an ocular tissue surface in groups of simultaneous points. A system for obtaining biomechanical parameters of ocular tissue includes an air-puff module to deliver an air-puff stimulus onto the ocular tissue, and an imaging device operatively coupled to the air-puff module. The air-puff module includes a transparent window at its front with a transparent through hole for delivering the air-puff stimulus. The hole is aligned with an imaging device optical axis, such that the air-puff stimulus delivered onto the ocular tissue can be centred on an apex of the ocular tissue and made collinear with the optical axis. The transparent window and through hole allow continuity of imaging of the ocular surface. The imaging device captures the 3D coordinates of points distributed on an ocular tissue surface in groups of simultaneous points. The system includes a component for selecting and changing location and distribution of captured points on the ocular tissue, and a processing component to process the points.

IPC Classes  ?

• A61B 3/16 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for measuring intraocular pressure, e.g. tonometers
• A61B 3/18 - Arrangement of plural eye-testing or -examining apparatus
• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions